Answers are grounded in this paper and cite their sources.
Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.
No takes yet. Share an insight, caveat, or question.
Davies et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: